Blastic plasmacytoid dendritic cell neoplasms – a report of two cases
暂无分享,去创建一个
O. Grzybowska-Izydorczyk | D. Jesionek-Kupnicka | T. Robak | E. Wawrzyniak | B. Pieńkowska-Grela | K. Jamroziak | A. Szmigielska-Kaplon
[1] M. Salama,et al. An unusual case of cutaneous blastic plasmacytoid dendritic cell neoplasm with concomitant B-cell lymphoproliferative disorder. , 2011, The American Journal of dermatopathology.
[2] Xiao-hong Chen,et al. Primary cutaneous blastic plasmacytoid dendritic cell neoplasm without extracutaneous manifestation: case report and review of the literature. , 2011, Pathology, research and practice.
[3] L. Cerroni,et al. Cutaneous Manifestations of Blastic Plasmacytoid Dendritic Cell Neoplasm—Morphologic and Phenotypic Variability in a Series of 33 Patients , 2010, The American journal of surgical pathology.
[4] R. Marchione,et al. CD4+/CD56+ Hematodermic neoplasm (plasmacytoid dendritic cell tumor). , 2008, Dermatology online journal.
[5] C. Massone,et al. CD4‐negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases , 2008, Journal of cutaneous pathology.
[6] E. Hsi,et al. CD4+/CD56+ hematodermic neoplasm (blastic NK‐cell lymphoma) , 2008, Journal of cutaneous pathology.
[7] Z. Argényi,et al. CD4+/CD56+ hematodermic neoplasm: report of a rare variant with a T‐cell receptor gene rearrangement , 2008, Journal of cutaneous pathology.
[8] S. Piña‐Oviedo,et al. CD4+/CD56+ Hematodermic Neoplasm: Presentation of 2 Cases and Review of the Concept of an Uncommon Tumor Originated in Plasmacytoid Dendritic Cells Expressing CD123 (IL-3 Receptor α) , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[9] G. Pinkus,et al. CD4+/CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. , 2007, American journal of clinical pathology.
[10] M. Herling,et al. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. , 2007, American journal of clinical pathology.
[11] M. Herling,et al. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms , 2006, Modern Pathology.
[12] K. Sułek,et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). , 2006, Blood.
[13] R. Dummer,et al. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. , 2005, Human pathology.
[14] C. Aul,et al. Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigenes , 2004, Annals of Hematology.
[15] T. Petrella,et al. `Agranular CD4+ CD56+ Hematodermic Neoplasm' (Blastic NK-Cell Lymphoma) Originates From a Population of CD56+ Precursor Cells Related to Plasmacytoid Monocytes , 2002, The American journal of surgical pathology.
[16] K. Ooya,et al. A cutaneous agranular CD2- CD4+ CD56+ "lymphoma": report of two cases and review of the literature. , 1998, American journal of clinical pathology.
[17] J. Bennett,et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. , 2012, Leukemia research.
[18] L. Shaffer,et al. ISCN 2009 - An International System for Human Cytogenetic Nomenclature , 2009 .
[19] M. Béné,et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. , 2003, Haematologica.